The drug also treats an overactive bladder. Oxybutynin significantly reduced hot flashes in men receiving prostate cancer hormone therapy. Prostate cancer risk increases with age, but younger men may ...

A phase 2 randomized, double-blind trial tested oxybutynin 2.5 mg BID and 5 mg BID versus placebo for six weeks in men on stable ADT with ≥28 weekly hot flashes. Dose-dependent efficacy was observed, ...

The journey through prostate cancer treatment marks a significant chapter in many men’s lives, with surgery often serving as a pivotal turning point toward recovery. While the removal of cancerous ...

Benign prostatic hyperplasia (BPH) is a non-cancerous prostate tissue growth affecting men 40 and older. BPH can cause difficulty urinating and may be exacerbated by some cold and allergy medications.

Please provide your email address to receive an email when new articles are posted on . Men with prostate cancer who received 5 mg twice-daily oxybutynin experienced ...

Postscreening data revealed substantial increases in interventions for bone health. Calcium supplementation rose from 16.3% to 44.2%, and prescriptions for bone-protective agent increased from 7.2% to ...

The prostate gland, nestled beneath the bladder and in front of the rectum, plays a vital role in male reproductive health by producing fluid for semen. While prostate cancer often develops slowly, ...

For men who have a detectable PSA of 0.5 ng/mL or less after radical prostatectomy and before salvage radiation therapy, hormone therapy may provide no overall survival or metastasis-free survival ...